MediGene, a Martinsried/Munich-based biotech, and The Johns Hopkins University will work together to create HPV vaccine candidates using the German firm's AAVLP platform. The preclinical program uses adeno-associated viruses as the basis for the vaccine and antigenic peptides to induce specific antibody reactions. MediGene hopes the platform can be used for viral infection and cancer vaccines as well. Release